Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial
Waters et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005716
https://c19early.org/waters2efm.html